ADL Amdl,

AMDL Comments on Canadian Lawsuit TUSTIN, Calif., Dec. 10 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL; Berlin, Frankfurt), developer and marketer of tests for the early detection of cancer and other serious diseases, today said that it was notified by the University of Alberta of an action that had been filed in Alberta, Canada arising out of Dr. Lung Chang's employment with the University and AMDL's acquisition of all of Dr. Chang's rights to the Combination Immunogene Therapy (CIT), which AMDL acquired on August 28, 2001 from Dr. Chang. The action is similar to the action filed in February 2002 by AcuVector, the terminated former licensee of the CIT technology. The University claims that AMDL was unjustly enriched and interfered with the contractual relationship between Dr. Chang, AcuVector and the University thereby inducing a breach of the University's rights. At the time AMDL acquired the CIT technology, AMDL received assurances from Dr. Chang and his attorneys that AcuVector's license rights had been terminated. AMDL believes it has meritorious defenses to both claims of the University and AcuVector. AMDL paid $2 million for the CIT technology and intends to vigorously defend the action and seek indemnification from Dr. Chang on both claims. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdlcorporate.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdlcorporate.com/

Copyright